Menu
Your Cart

About Us


Apostle Inc is a biotechnology company and a provider of innovative technologies and services for public health and life sciences. The company owns and operates its headquarters at: 3589 Nevada St, Pleasanton, CA 94566.

Apostle aims to develop best-in-class nucleic acid isolation and preservation technologies. Specifically, we aim to develop innovative technologies in the field of circulating free DNA (cfDNA), used in noninvasive prenatal testing (NIPT) and liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing cfDNA as a biomarker. Our innovations include Apostle MiniMax, a best-in-class and automatable solution to efficiently capture cfDNA from a standard blood draw; Apostle MagTouch, a nucleic acids isolation automation system, and Apostle MiniEnrich, a high-resolution DNA size enrichment technology using a magnetic nano-platform.

In addition, Apostle also provides the MiniGenomics product series, providing efficient, scalable, and reproducible isolation of high-quality genomic DNA and/or RNA from a variety of biological specimens. The Apostle MiniGenomics product series has contributed significantly to the flight against COVID-19 during the recent pandemic.

Apostle technologies have been widely applied in many world-class R&D studies, clinical laboratory settings, and public health response and surveillance. These applications have resulted in many high-profile scientific publications including Nature Medicine, Nature Communications, Science Translational Medicine, PNAS, etc. To date, the company's products have served over 20 million people, while we are continuing to improve our technologies and products to further our mission to benefit public health and life sciences.

Apostle Inc is pleased to receive the Certificates of Conformance to certify that Quality Management System of Apostle Inc. has been assessed by ABS Quality Evaluations, Inc. and found to be in conformance with the requirements set forth by: ISO13485:2016, and ISO9001:2015. The Quality Management System is applicable to DEVELOPMENT, MANUFACTURING, LICENSING AND SALES OF CONSUMABLES AND CHEMICALS FOR NUCLEIC ACID RESEARCH. Apostle Inc holds a Medical Device Manufacturing License issued by State of California, Department of Public Health, Food and Drug Branch. In addition, Apostle Inc is also a clinical laboratory authorized by the US federal CLIA (CLIA ID 05D2191922), accredited by College of American Pathologists (CAP Number 8830916), with a Clinical and Public Health Laboratory License issued by the California state government. Click the images below to access the certificates and accreditations.

Current Accreditations

Recognitions and Awards

Team - Scientific Advisory Board

Team - Management

All Publications

Apostle technologies have been cited or used by scientists from the following organizations. Click to read more when there is a publication.

Track Record of Publications

Recognitions

  • Feb 1, 2024, A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. 
  • JAN 2, 2024, Apostle MiniMax Technology is used in and cited by an independent clinical study to analyze cfRNA on transcriptome-wide characterizations in 165 lung cancer, 30 breast cancer, 37 colorectal cancer, 55 gastric cancer, 15 liver cancer, and 133 cancer-free participants and demonstrate its ability to identify transcriptomic changes occurring in early-stage tumors, published in Nature Communications.
  • APR 10, 2023, Apostle MiniMax Technology is cited by a new independent clinical study  including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection, published in Nature Communications.
  • NOV 23, 2022, Apostle MiniMax Technology is cited by another independent clinical study demonstrating the successful clinical utility and validity of the circulating cell-free DNA (cfDNA) analysis for hepatocellular carcinoma (HCC) detection with high sensitivity and specificity, published in Science Translational Medicine.
  • AUG 18, 2022, Apostle MiniMax Technology is cited by a new independent clinical study, published in Nature Medicine by a joint clinical team from Gritstone, Columbia University Medical Center, Mayo Clinic, MSKCC, MD Anderson, showing “exploratory biomarker analyses showed decreased circulating tumor DNA (ctDNA) in patients with prolonged OS”.
  • JUN 14, 2022, Clinical Study Supports the Use of Liquid Biopsy for Early Diagnosis and Monitoring of Patients with Myeloid Neoplasms, Citing Apostle MiniMax Technology.  
  • APR 11, 2022, Apostle MiniMax Technology is cited by an independent clinical study, published in Nature Medicine, studying safety and tolerability of AAV8 delivery of a broadly neutralizing antibody. 
  • JAN 28, 2022, Performance of Apostle technology is independently validated in an independent study by scientists from Johns Hopkins University and University of Pittsburgh, published in SLAS Technology, showed that, "(Page 6, Figure 4) Most notably, the Apostle particles outperformed all others, achieving almost 2-fold higher recovery yields than the particles supplied in the X kit".
  • AUG 30, 2021, Apostle Inc Apostle Diagnostics Laboratory Receives Accreditation from College of American Pathologists.
  • APR 12, 2021, Apostle RNA Extraction Method is Included in a US FDA EUA Authorized SARS-CoV-2 Molecular Diagnostic Test: Fulgent COVID-19 by RT-PCT Test.
  • FEB 2, 2021, Apostle MiniMax Technology In Novel Liquid Biopsy Method for Detecting and Monitoring Colon Cancer, Published in PNAS.
  • SEPT 7, 2020, Apostle MiniEnrich Technology is Published in Royal Society of Chemistry’s Analyst.
  • MAY 24, 2019, Apostle Inc Completes Series A Financing Led by ShangBay Capital, Palo Alto, CA.
  • FEB 28, 2019, Apostle Inc. Enters Partnership with Beckman Coulter Life Sciences.
  • APR 3, 2018, Apostle is Elected into the Stanford University StartX Accelerator Program.

 

Apostle Diagnostics

Headquarters: 3589 Nevada St, Pleasanton, CA 94566

Headquarters: 3589 Nevada St, Pleasanton, CA 94566
Headquarters: 3589 Nevada St, Pleasanton, CA 94566
Apostle Team
Headquarters: 3589 Nevada St, Pleasanton, CA 94566
Headquarters: 3589 Nevada St, Pleasanton, CA 94566
All Publications
Contact Us
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.